The combination of CXCR4 therapeutic agent blockade and PDCD1 resulted in the reduction of suppressive leukocytes and promoted the transition of M2-to-M1 macrophage polarization within the tumor (Pei et al., 2023). The gene discussed is CXCR4; the disease is neoplasm.